News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
61
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8313
|
|
Created
|
08/20/01
|
Type
|
Free
|
| Moderators | |||
Outstanding Shares: 13,692,179 shares.
Floating Shares: 7,370,000 Shares.
Shorting Shares: 110,181 Shares On 04/30/2012.
Insiders Ownership: 40.91%.
Institution Ownership: 3,247,785 shares or 23.72%.
(Pope alone owns 2,234,088 shares or 16.32% of OS)
Shareholder's Equity: $184,707,495.
Book Value: $13.49 Per Share.
Total Cash: $146,930,000.
Cash Value: $10.73 Per Share.
Revenue: $98,510,000.
Revenue Per Share: $7.88.
Gross Profit: $71,350,000.
Diluted EPS: $2.56.
Operating Cash Flow: $47,780,000.
Leveled Free Cash Flow: $24,310,000.
52-Week Range Before Halt: $3.01 ~ $10.98.
52-Week Range After Halt: $0.0811 ~ $0.8.
| Middle Section, Longmao Street Area A Laiyang Waixiangxing Industrial Park Laiyang City, Yantai, 265200 China | |
|
Jiangbo Pharmaceuticals, Inc. engages in research, development, production, marketing and sales of pharmaceutical products in People's Republic of China ("PRC") through its operating subsidiary, Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("Laiyang Jiangbo"). Jiangbo purchases patents for drugs or develops sophisticated drugs through collaboration with leading research institutions. The Company is well positioned to benefit from rapidly growing pharmaceutical market in China by its well known brand, experienced management, skilled workforce and extensive distribution network.The company is located in Northeast China in an Economic Development Zone, Laiyang City ,Shandong Province.
Jiangbo has 470 full time sales representatives and 620 part time representatives located in all major commerce areas across China. The company has numerous GMP (Chinese State Drug Administration or the SDA) approved manufacturing facilities and production lines,to produce various forms of Traditional Chinese Medicines and Western Medicines. The Company has a production capacity of 6 billion tablets, 70 million boxes of granules and 50 million boxes of capsules. 12 million bottles of Syrup and 8 million bottles of electuary. The acquisition of Hongrui in January 2009 increased Jiangbo' product portfolio from 6 to 28 products. The Company's best selling products include Clarithromycin sustained-release tablets, Itopride Hydrochloride granules, Baobaole Chewable Tablets, Radix Isatidis Dispersible Tablets. Currently Jiangbo has three new products in the pipeline awaiting final SFDA approval.
English
http://www.jiangbopharma.com/
Chinese
http://www.jiangbo.cn/
Chinese (Translated...use the linkbottoms on the bottom , they work) :
http://translate.google.de/translate?js=y&prev=_t&hl=de&ie=UTF-8&layout=1&eotf=1&u=http%3A%2F%2Fwww.jiangbo.cn&sl=zh-CN&tl=en
AI
